Edition:
United States

DexCom Inc (DXCM.O)

DXCM.O on Nasdaq

74.94USD
27 Jun 2017
Change (% chg)

-- (--)
Prev Close
$74.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,034,467
52-wk High
$96.38
52-wk Low
$57.68

Latest Key Developments (Source: Significant Developments)

Dexcom announces FDA approval of G5 mobile app for android devices
Wednesday, 7 Jun 2017 08:00am EDT 

June 7 (Reuters) - Dexcom Inc :Dexcom announces fda approval of g5 mobile app for android devices.Dexcom Inc - ‍food and drug administration (fda) approval of dexcom g5 mobile app for android devices​.  Full Article

Dexcom prices offering of $350 mln of 0.75% convertible senior notes
Monday, 8 May 2017 08:04pm EDT 

May 8 (Reuters) - Dexcom Inc :Prices offering of $350 million of 0.75% convertible senior notes.Pricing of its offering of $350 million aggregate principal amount of 0.75% convertible senior notes due 2022.Notes will be senior, unsecured obligations of dexcom, and will bear interest at a rate of 0.75% per year, payable semi-annually in arrears.  Full Article

Dexcom announces proposed offering of convertible senior notes
Monday, 8 May 2017 07:09am EDT 

May 8 (Reuters) - Dexcom Inc :Dexcom announces proposed offering of $300 million of convertible senior notes.Intends to offer $300 million aggregate principal amount of convertible senior notes due 2022.Notes will be senior, unsecured obligations of Dexcom, and interest will be payable semi-annually in arrears.Notes will mature on May 15, 2022.Expects to use net proceeds of offering of notes to repay $75 million of borrowings under its existing credit facility.  Full Article

Dexcom reports Q1 revenue $142.3 million
Tuesday, 2 May 2017 04:01pm EDT 

May 2 (Reuters) - Dexcom Inc :Dexcom, Inc. Reports first quarter 2017 financial results.Q1 GAAP loss per share $0.49.Q1 revenue $142.3 million versus I/B/E/S view $144.4 million.Q1 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Dexcom Inc says committed to borrow $75 mln in principal amount under its existing $200 mln revolving credit facility - SEC filing
Monday, 6 Mar 2017 09:20am EST 

Dexcom Inc : Dexcom Inc - on February 28, 2017, co committed to borrow $75 million in principal amount under its existing $200 million revolving credit facility - SEC filing . Dexcom Inc - borrowed funds were received by Dexcom on March 3, 2017 .Dexcom Inc - term of borrowing is six months and total interest anticipated on borrowing during that period is approximately $1.2 million.  Full Article

Dexcom Q4 gaap loss per share $0.09
Tuesday, 28 Feb 2017 04:01pm EST 

Dexcom Inc : Dexcom, inc. Reports fourth quarter and fiscal year 2016 financial results . Q4 gaap loss per share $0.09 . Q4 revenue $171.2 million versus i/b/e/s view $168 million .Q4 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Dexcom says chief financial officer to resign, effective as of April 1
Tuesday, 21 Feb 2017 09:12am EST 

Dexcom Inc : Dexcom Inc- on Feb 14 Jess Roper, chief financial officer notified Dexcom of his decision to resign, effective as of April 1, 2017 - sec filing .Dexcom Inc - upon Roper's resignation, Dexcom will appoint Kevin Sun, as interim chief financial officer.  Full Article

Baillie Gifford & Co reports 7.25% passive stake in Dexcom Inc as of Dec 31, 2016
Friday, 20 Jan 2017 10:49am EST 

Baillie Gifford & Co:Reports 7.25 percent passive stake in Dexcom Inc as of 31 December 2016 - SEC filing.  Full Article

Dexcom reports record preliminary, unaudited revenue for the Q4 and fiscal year 2016
Tuesday, 10 Jan 2017 08:30am EST 

Dexcom Inc : Dexcom reports record preliminary, unaudited revenue for the fourth quarter and fiscal year 2016 and provides initial 2017 outlook . Sees FY 2017 revenue $710 million to $740 million . Q4 revenue $168 million versus I/B/E/S view $167.5 million . Sees FY 2016 revenue up 42 percent . Sees FY 2016 revenue $570 million . Gross margin is expected to range from 67 pct to 70 pct for 2017 . 2017 operating expenses are anticipated to increase by approximately 20 pct to 25 pct over 2016 .At end of 2017, company is targeting a patient base of 270,000 worldwide.  Full Article

U.S. FDA expands approved use of Dexcom’s G5 mobile continuous glucose monitoring system
Tuesday, 20 Dec 2016 02:53pm EST 

U.S. Food and Drug Administration : The u.s. Fda expands approved use of dexcom’s g5 mobile continuous glucose monitoring system . u.s. Fda - fda expands indication for continuous glucose monitoring system, first to replace fingerstick testing for diabetes treatment decisions Further company coverage: [DXCM.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

BRIEF-Dexcom announces FDA approval of G5 mobile app for android devices

* Dexcom announces fda approval of g5 mobile app for android devices